WASHINGTON — A genetic variant commonly found in some Africans may stymie the effects of a popular breast cancer drug.
The variant produces a sluggish version of the enzyme known to activate tamoxifen. People who inherit two copies of the variant show five times less active drug in their bloodstreams compared with people who don’t have that variant, researchers reported November 2 at the American Society of Human Genetics annual meeting.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.
Use up and down arrow keys to explore.Use right arrow key to move into the list.Use left arrow key to move back to the parent list.Use tab key to enter the current list item.Use escape to exit the menu.Use the Shift key with the Tab key to tab back to the search input.